Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 348,025	$ 162,598
Cost of revenue:
Cost of revenue	61,291	57,533
Depreciation	11,263	7,428
Total cost of goods sold	72,554	64,961
Gross profit	275,471	97,637
Operating expenses
Selling, general and administrative expenses	2,508,371	2,694,395
Research and development expenses	73,520	104,180
Total operating expenses	2,581,891	2,798,575
Loss from operations	(2,306,420)	(2,700,938)
Other income (expense):
Loss from equity method joint ventures	(27,735)	(71,117)
Interest income		225
Interest expense	(216,589)	(1,456)
Foreign currency exchange loss	(135)	(1,026)
Total other income (expense)	(244,459)	(73,374)
Net loss	$ (2,550,879)	$ (2,774,312)
Net loss per common share:
Basic	$ (0.20)	$ (0.23)
Diluted	$ (0.20)	$ (0.23)
Weighted average number of common shares outstanding:
Basic	12,450,072	12,050,696
Diluted	12,450,072	12,050,696
Product [Member]
Revenue:
Total revenue	$ 50,644	$ 56,750
Clinic Revenue [Member]
Revenue:
Total revenue	$ 297,381	$ 105,848